Capecitabine in Low Risk Triple Negative Breast Cancer

Summary

This study aims to evaluate the efficacy and safety of capecitabine as the only adjuvant chemotherapy drug in patients with low-risk early triple-negative breast cancer who have received adequate local treatment. Patients meeting the inclusion criteria will receive capecitabine metronomic therapy for one year.

Timeline

Start

2025-01-15

Primary completion

2028-12-31

Completion

2030-01-31

Drugs

Indications